Literature DB >> 23930824

Low incidence of Pneumocystis jirovecii pneumonia in an unprophylaxed liver transplant cohort.

S Sarwar1, B Carey, J E Hegarty, P A McCormick.   

Abstract

BACKGROUND: Liver transplant recipients are managed with a range of immunosuppressive regimens that place them at heightened risk of life-threatening opportunistic infections such as Pneumocystis jirovecii pneumonia (PJP). No routine PJP prophylaxis is used at out institution. We reviewed the incidence of PJP in this cohort of unprophylaxed liver transplant recipients.
METHODS: We examined all liver transplants performed between January 2000 and January 2012 in Ireland's National Liver Transplant Centre, St. Vincent's University Hospital, Dublin. Cases were identified through a computerized database and through the histopathology and microbiology registration system. The diagnosis of PJP was confirmed by identification of Pneumocystis cysts in bronchoalveolar lavage (BAL) fluid or on autopsy specimens using Grocott-Gomori methenamine-silver nitrate or modified Wright-Giemsa staining methods.
RESULTS: During the study period, 687 liver transplants were performed. We found 7 cases of PJP with an incidence rate of 0.84 per 1000 person transplant years. Five cases occurred within 12 months of transplant with 2 cases occurring at 56 and 60 months, respectively. Two cases were diagnosed at postmortem; 1 previously had negative cytology from BAL, while the other could not be bronchoscoped because of rapid deterioration in the clinical condition. Three of the 5 treated patients died.
CONCLUSIONS: The incidence of PJP in this cohort was very low, but the case fatality rate was high. Two cases occurred well after the usual recommended period of prophylaxis. In institutions with a very low risk of infection, targeted rather than universal prophylaxis may be reasonable.
© 2013 John Wiley & Sons A/S.

Entities:  

Keywords:  PCP; PJP; Pneumocystis jirovecii pneumonia; liver transplantation; opportunistic infections; prophylaxis

Mesh:

Substances:

Year:  2013        PMID: 23930824     DOI: 10.1111/tid.12117

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  5 in total

Review 1.  Pentamidine in Pneumocystis jirovecii prophylaxis in heart transplant recipients.

Authors:  Adem Ilkay Diken; Ozlem Erçen Diken; Onur Hanedan; Seyhan Yılmaz; Ata Niyazi Ecevit; Emir Erol; Adnan Yalçınkaya
Journal:  World J Transplant       Date:  2016-03-24

2.  Pneumocystis pneumonia in liver transplant recipients.

Authors:  Xian-Liang Li; Zi-Xi Liu; Zhen-Jia Liu; Han Li; Benjamin Wilde; Oliver Witzke; Man Qi; Wen-Li Xu; Qiang He; Ji-Qiao Zhu
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 3.  Pneumocystis jiroveci pneumonia prophylaxis in patients with autoimmune hepatitis.

Authors:  Patrick Stauffer; Joseph Ahn
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-07-22

4.  Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis.

Authors:  Philip B Andreasen; Omid Rezahosseini; Dina L Møller; Neval E Wareham; Magda T Thomsen; Ranya Houmami; Andreas D Knudsen; Jenny Knudsen; Jørgen A L Kurtzhals; Andreas A Rostved; Christian R Pedersen; Allan Rasmussen; Susanne D Nielsen
Journal:  Immun Inflamm Dis       Date:  2021-10-29

5.  Is Routine Prophylaxis Against Pneumocystis jirovecii Needed in Liver Transplantation? A Retrospective Single-Centre Experience and Current Prophylaxis Strategies in Spain.

Authors:  José Ignacio Fortea; Antonio Cuadrado; Ángela Puente; Paloma Álvarez Fernández; Patricia Huelin; Carmen Álvarez Tato; Inés García Carrera; Marina Cobreros; María Luisa Cagigal Cobo; Jorge Calvo Montes; Carlos Ruiz de Alegría Puig; Juan Carlos Rodríguez SanJuán; Federico José Castillo Suescun; Roberto Fernández Santiago; Juan Andrés Echeverri Cifuentes; Fernando Casafont; Javier Crespo; Emilio Fábrega
Journal:  J Clin Med       Date:  2020-11-06       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.